Skip to content
Research/Nad Mitochondrial/NAD+ IV Infusion

NAD+ IV Infusion

IV therapy. IV infusion bypasses digestion for rapid NAD+ elevation. Direct NAD+ replenishment; activates sirtuins, PARPs; supports mitochondrial function and DNA repair. Typically 500mg-1000mg per session.

Intelligence Profile

Clinical Applications

The clinical evidence for NAD+ IV infusion is extremely limited, with only a small number of published studies examining its therapeutic applications and safety profile.

Anti-Aging and Wellness Applications

One systematic review (2026) examined NAD+ supplementation for anti-aging and wellness purposes, though this review encompassed various forms of NAD+ supplementation including oral routes, not specifically IV infusion. The review's findings regarding IV-specific applications are not detailed in the available evidence.

Pharmacokinetic and Safety Studies

The most relevant clinical data comes from a pilot study (2019) that investigated changes in plasma and urine NAD+ metabolites during a 6-hour intravenous infusion of NAD+. This study appears to have focused primarily on understanding how IV NAD+ affects metabolite levels rather than therapeutic outcomes for specific conditions.

A retrospective tolerability study (2026) compared intravenous NAD+ infusion with oral nicotinamide riboside (NR) in a real-world clinical setting, suggesting that IV NAD+ is being used in clinical practice, though the specific conditions treated and efficacy outcomes are not detailed in the available abstracts.

Evidence Limitations

The clinical evidence base for NAD+ IV infusion is notably sparse. The available studies appear to focus primarily on pharmacokinetics, safety, and tolerability rather than demonstrating therapeutic efficacy for specific medical conditions. No large-scale randomized controlled trials specifically evaluating NAD+ IV infusion for defined clinical endpoints were identified in the evidence provided.

Important Note: This information is for educational purposes only and should not be considered medical advice. Consult with a qualified healthcare provider before considering any NAD+ IV therapy, as the clinical evidence remains limited and safety profiles are not fully established.

The lack of robust clinical trial data means that many claimed benefits of NAD+ IV infusion are not yet supported by high-quality evidence, and more research is needed to establish both efficacy and safety for specific therapeutic applications.

Free account required

Clinical data requires a free AXIFI account to access clinical data, safety profiles, and research papers.